<DOC>
	<DOCNO>NCT02924337</DOCNO>
	<brief_summary>The purpose study assess effect single therapeutic dose single supra-therapeutic dose imeglimin QT/QTc interval</brief_summary>
	<brief_title>Effect Imeglimin QT/QTc Intervals Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>healthy volunteer BMI 18.5 29.9 kg/m2 weigh 55 95 kg willing use reliable contraception able give fully inform write consent . Pregnant lactate woman , sexually active woman childbearing potential use highly effective contraception clinically relevant abnormal medical history , surgery concurrent medical condition ; acute chronic illness clinically significant QT/QTc interval prolongation Baseline history druginduced risk factor Torsade de Pointes contraindication moxifloxacin severe adverse reaction drug sensitivity trial medication component significant food allergy ; use vitamin , herbal medicine , prescription overthecounter medication ( exception paracetamol [ acetaminophen ] oral contraceptive woman ) within 20 day 6 halflives first dose trial medication participation clinical trial unlicensed prescription medicine , loss 400 mL blood , within 3 month first dose trial medication drug alcohol abuse ; smoke 5 cigarette , 1 cigar 1 pipe daily regular consumption 5 cup caffeinated drink per day positive test hepatitis A , B &amp; C , HIV objection General Practitioner .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>QT/QTC interval</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Imeglimin</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>